intetumumab
mAbexperimental
Intetumumab is a human monoclonal antibody targeting integrins that was being studied for the treatment of solid tumors. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00246012)
Timeline
Indications
Mechanism of action
- Integrin alpha-V/beta-3ANTAGONIST
Integrin alpha-V/beta-3 antagonist
- Integrin alpha-V/beta-5ANTAGONIST
Integrin alpha-V/beta-5 antagonist
- Integrin alpha-V/beta-6ANTAGONIST
Integrin alpha-V/beta-6 antagonist
- Integrin alpha-V/beta-1ANTAGONIST
Integrin alpha-V/beta-1 antagonist
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIntetumumab ↗
- ChEMBLCHEMBL1743032 ↗
Also known as
- cnto-095
- cnto 95
- cnto 95
- cnto-95
- cnto 95 monoclonal antibody
- intetumumab
- intetumumab
- intetumumab
- intetumumab
- monoclonal antibody cnto 95
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00888043 | Phase 1 | Mar 1, 2009 | Centocor, Duke University, Genentech |
| NCT00537381 | Phase 2 | May 1, 2007 | Centocor |
| NCT00246012 | Phase 1/Phase 2 (Phase 2) | May 1, 2005 | Centocor, Johnson and Johnson |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centocor | For profit | 3 | 2 | 2 | 2005 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Genentech | For profit | 1 | 0 | 1 | 2009 |
| Johnson and Johnson | For profit | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1